These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11006134)

  • 21. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Farnesyl transferase inhibitors in clinical development.
    Caponigro F; Casale M; Bryce J
    Expert Opin Investig Drugs; 2003 Jun; 12(6):943-54. PubMed ID: 12783599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.
    Njoroge FG; Vibulbhan B; Shi X; Strickland C; Kirschmeier P; Bishop R; Nomeir A; Girijavallabhan V
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5899-902. PubMed ID: 15501065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids.
    Hohl RJ; Lewis KA; Cermak DM; Wiemer DF
    Lipids; 1998 Jan; 33(1):39-46. PubMed ID: 9470172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Farnesyl transferase inhibitors as anticancer agents.
    Haluska P; Dy GK; Adjei AA
    Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clavaric acid: a triterpenoid inhibitor of farnesyl-protein transferase from Clavariadelphus truncatus.
    Jayasuriya H; Silverman KC; Zink DL; Jenkins RG; Sanchez M; Pelaez F; Vilella D; Lingham RB; Singh SB
    J Nat Prod; 1998 Dec; 61(12):1568-70. PubMed ID: 9868169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesyltransferase inhibitors versus Ras inhibitors.
    Gibbs JB; Graham SL; Hartman GD; Koblan KS; Kohl NE; Omer CA; Oliff A
    Curr Opin Chem Biol; 1997 Aug; 1(2):197-203. PubMed ID: 9667853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models.
    Liu M; Bishop WR; Nielsen LL; Bryant MS; Kirschmeier P
    Methods Enzymol; 2001; 333():306-18. PubMed ID: 11400347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Farnesyl transferase inhibitors: the successes and surprises of a new class of potential cancer chemotherapeutics.
    Buss JE; Marsters JC
    Chem Biol; 1995 Dec; 2(12):787-91. PubMed ID: 8807811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kampanols: novel Ras farnesyl-protein transferase inhibitors from Stachybotrys kampalensis.
    Singh SB; Zink DL; Williams M; Polishook JD; Sanchez M; Silverman KC; Lingham RB
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2071-6. PubMed ID: 9873488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.
    Gibbs JB; Pompliano DL; Mosser SD; Rands E; Lingham RB; Singh SB; Scolnick EM; Kohl NE; Oliff A
    J Biol Chem; 1993 Apr; 268(11):7617-20. PubMed ID: 8463291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes.
    Mirza UA; Chen G; Liu YH; Doll RJ; Girijavallabhan VM; Ganguly AK; Pramanik BN
    J Mass Spectrom; 2008 Oct; 43(10):1393-401. PubMed ID: 18438977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformation of a novel tetrapeptide inhibitor NH2-D-Trp-D-Met-Phe(pCl)-Gla-NH2 bound to farnesyl-protein transferase.
    Bogusky MJ; Culberson JC; Pitzenberger SM; Garsky VM; Wallace A; Pessi A; Koblan KS
    J Pept Res; 1999 Jul; 54(1):66-73. PubMed ID: 10448971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein farnesyltransferase inhibitors.
    Head JE; Johnston SR
    Expert Opin Emerg Drugs; 2003 May; 8(1):163-78. PubMed ID: 14610919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diaryl ether inhibitors of farnesyl-protein transferase.
    Mactough SC; Desolms SJ; Shaw AW; Abrams MT; Ciccarone TM; Davide JP; Hamilton KA; Hutchinson JH; Koblan KS; Kohl NE; Lobell RB; Robinson RG; Graham SL
    Bioorg Med Chem Lett; 2001 May; 11(10):1257-60. PubMed ID: 11392531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited.
    Hill BT; Perrin D; Kruczynski A
    Crit Rev Oncol Hematol; 2000 Jan; 33(1):7-23. PubMed ID: 10714959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of triton concentration on the activity of undecaprenyl pyrophosphate synthase inhibitors.
    Li H; Huang J; Jiang X; Seefeld M; McQueney M; Macarron R
    J Biomol Screen; 2003 Dec; 8(6):712-5. PubMed ID: 14711397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel reverse-turn mimics inhibit farnesyl transferase.
    Liu R; Dong DL; Sherlock R; Nestler HP; Gennari C; Mielgo A; Scolastico C
    Bioorg Med Chem Lett; 1999 Mar; 9(6):847-52. PubMed ID: 10206548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease.
    Sjogren AK; Andersson KM; Khan O; Olofsson FJ; Karlsson C; Bergo MO
    Leukemia; 2011 Jan; 25(1):186-9. PubMed ID: 20975663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.